ABSTRACT
by 47% compared to control hearts (P<0.01). In GYY4137-treated hearts,
49
phosphorylation of Akt, eNOS and GSK-3β was increased 2.8, 2.2 and 2.2 fold 50 respectively at early reperfusion. Co-administration of L-NAME and GYY4137 51 attenuated the cardioprotection afforded by GYY4137, associated with attenuated 52 phosphorylation of eNOS. LY294002 totally abrogated the infarct-limiting effect of 53 GYY4137 and inhibited Akt, eNOS and GSK-3β phosphorylation. These data are the 54 first to demonstrate that GYY4137 protects the heart against lethal reperfusion injury 
INTRODUCTION

78
In acute myocardial infarction, prompt restoration of coronary blood flow with 79 appropriate reperfusion interventions is essential to salvage ischemic myocardium.
80
Paradoxically, sudden reperfusion induces further irreversible cell injury and death
81
beyond that caused by ischemia. Therefore, reperfusion injury contributes to overall 82 clinical outcome since ultimate infarct size will be determined by both ischemic and 83 reperfusion injuries . Reperfusion injury is a challenging but (Zhao et al., 2003) . This intervention has been shown to limit infarct size significantly, 94 most likely through the activation of survival signalling mechanisms that reduce 95 opening of the mPTP (Hausenloy and Yellon, 2007 vasculature (Liu et al., 2012, Hackfort and Mishra, 2016) , in coronary artery disease,
108
there may be reduced H 2 S production (Yong et al., 2008 , Han et al., 2015 , Islam et 109 al., 2015 . The administration of exogenous H 2 S donor compounds or increasing 110 endogenous production of H 2 S has been well documented to reduce ischemia-
111
reperfusion injury in experimental models (Elrod et al., 2007 , Calvert et al., 2009 , 112 King et al., 2014 . There is also evidence that H 2 S is a mediator of IPost-C (Bian et 113 al., 2006 , Yong et al., 2008 , Huang et al., 2012 , Das et al., 2015 . In contrast to Na 2 S and NaSH, GYY4137 (morpholin-121 4-ium 4-methoxyphenyl-morpholino-phosphinodithioate) is a donor compound which 122 releases H 2 S at a slow steady rate at physiological pH and temperature (Li et al., 123 2008). Several studies have suggested that GYY4137 effectively delivers H 2 S in 124 various physiological systems (Li et al., 2009 , Lisjak et al., 2010 , Lee et al., 2011 Robinson and Wray, 2012, Liu et al., 2013 , Grambow et al., 2014 2015b). Recent work by Meng et al. (2015a) showed that GYY4137 given prior to 
Materials
156
GYY4137 was synthesised by us as previously reported (Li et al., 2008 
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After 120 min reperfusion, the heart was excised and perfused via the aorta with range employed in these studies was derived from previous studies in the rat heart 221 ex vivo by our group (Suveren et al., 2012) and in vivo studies conducted by others 222 (Li et al., 2008 , Meng et al., 2015a . Animals were randomly assigned to one of five 223 groups ( Figure 1A ): 
RESULTS
In series 1, 42 rats were used, of which two were excluded from final analysis, one due to failure of TTC staining and one rat which did not survive the ischemiareperfusion protocol. Thus data for 40 successfully completed experiments are reported. In series 2, 66 rats were employed, of which three did not complete the ischemia-reperfusion protocol. Thus, data from a total of 63 completed experiments are reported in series 2: these comprised 39 completed infarct size experiments and 24 preparations for Western blot analysis.
Hemodynamic parameters
Baseline hemodynamics for series 1 and 2 are summarised in Table 1 . There was no significant difference in any of the parameters among the experimental groups.
Cardiodynamics (MAP and RPP) measurements before ischemia, during ischemia and at the end of reperfusion are also presented in Table 1 . GYY4137 had no detectable effect on cardiodynamics during the ischemia-reperfusion protocol.
Infarct size following GYY4137 postconditioning
Series 1 examined the response to three doses of GYY4137 on infarct size ( Figure   2 ). AAR constituted approximately 40-60% of the total ventricular volume with no significant differences among the treatment groups ( Figure 2A ). Control infarct size (%I/AAR) was 52.5 ± 4.7% ( Figure 2B ). GYY4137 (266 µmol kg -1 ) produced significant infarct limitation when given 10 minutes before reperfusion compared to control hearts (27.9 ± 3.8% vs 52.5 ± 4.7%, p<0.01). This represents a 47% relative reduction in infarct size. In contrast, depleted-GYY4137 (produced as described in Alexander et al., 2015) which lacked H 2 S donating potential but was otherwise structurally identical had no effect on infarct size at the same dose (51.9 ± 3.1%), confirming the dependency of GYY4137's infarct-limiting action on H2S release.
Involvement of PI3K/Akt and eNOS in GYY4137 postconditioning
The second series of experiments was undertaken to examine components of the RISK signalling pathway in the protective effect of GYY4137 (Figure 3 ). There was no significant difference in the AAR among the experimental groups ( Figure 3A ).
GYY4137 (266 µmol kg -1 ) elicited a significant reduction in %I/AAR compared to control (27.6 ± 2.0% vs 56.8 ± 3.5%, respectively, p<0.001, Figure 3B ).
Pharmacological inhibition of eNOS with L-NAME prior to GYY4137 almost halved the cardioprotective effect of GYY4137 (41.1 ± 6.3% vs 27.6 ± 2.0%, respectively, p<0.05), but did not abolish it (41.1 ± 6.3% vs 56.8 ± 3.5%, respectively, p<0.01, Figure 3B ). Concomitant administration of LY294002 to inhibit PI3K activity completely abrogated the cardioprotective effect of GYY4137 (49.8 ± 4.2% vs 56.8 ± 3.5%, respectively, p>0.05). Neither L-NAME nor LY294002 had any effect on infarct size when given alone (55.7 ±3.3% and 51.2 ± 2.7% respectively, both p>0.05 vs control).
The extent of phosphorylation of Akt, eNOS, GSK-3β and ERK1/2 in early reperfusion was investigated with phospho-specific antibodies to determine the possible roles in cardioprotection by GYY4137. Immunoreactivity measurements were performed using myocardial tissue samples harvested from the left ventricle 5 minutes after reperfusion and are presented in Figure 4A -D. There was no significant difference in protein expression to GAPDH of Akt, eNOS, GSK-3β or ERK1/2 among any of the experimental groups. There was a significant 2.8-fold increase (p<0.001 vs. control) in phospho-ser 473 Akt at reperfusion following GYY4137 treatment ( Figure 4A ). Prior administration of L-NAME did not limit this increase in Akt phosphorylation. However, administration of LY294002 alone or prior to GYY4137 abolished Akt phosphorylation ( Figure 5A ). Postconditioning with GYY4137 also increased eNOS phosphorylation at the activating ser 1177 site by 2.2-fold in early reperfusion (p<0.01 vs. control; Figure 4B ). This activation was abrogated by prior administration of either L-NAME or LY294002. Ser 9 phosphorylation of GSK-3β was also increased 2.2-fold by GYY4137 ( Figure 4C ).
This phosphorylation, leading to inactivation of GSK-3β, was not affected L-NAME.
However, pre-treatment with LY294002 prior to GYY4137 abrogated GSK-3β phosphorylation. GYY4137 had no significant effect on the phosphorylation of ERK1/2 at early reperfusion ( Figure 4D ).
DISCUSSION
The principal observations of this study can be summarised as follows:
1. GYY4137 limited myocardial infarction in vivo when given specifically prior to reperfusion indicating potent attenuation of lethal reperfusion injury in a postconditioning-like manner.
2. The infarct-limiting effect of GYY4137 at early reperfusion was mediated through activation of the PI3K/Akt survival cascade.
3. There was a partial dependency of GYY4137's protective effect on increased eNOS activation.
4. GYY4137 inhibited GSK-3β activity at early reperfusion by increasing the phosphorylation of its ser 9 site downstream of PI3K/Akt signalling.
These findings support the hypothesis that administration of GYY4137 at reperfusion can protect the heart against reperfusion injury by activating the key components of the RISK cascade (PI3K/Akt/NO) and inhibition of GSK-3β activity.
Infarct limitation by GYY4137
The results show for the first time the effect of GYY4137, as a slow-releasing H 2 S donor, on myocardial infarction in an in vivo model. Intracellular levels of H 2 S are reported to be decreased during ischaemia-reperfusion as a results of overwhelming ROS generation which limits H 2 S synthesis and increases its degradation (Vandiver and Snyder, 2012) . GYY4137 elicited significant infarct limitation when administered prior to reperfusion. Depleted GYY4137 (Alexander et al., 2015) was employed as a control to ensure that any detectable effect was due to H 2 S released and not by the parent molecule or by-products formed from GYY4137 decomposition. Depleted GYY4137 had no effect on infarct size and this is consistent with previous studies where loss of H 2 S from GYY4137 was shown to be associated with loss of biological activity (Li et al., 2009 , Fox et al., 2012 , Jamroz-Wisniewska et al., 2014 , Alexander et al., 2015 . This is the first study of pharmacological postconditioning against reperfusion injury in vivo using GYY4137 as a stable H 2 S donor. Although inorganic H 2 S generators (NaSH and Na 2 S) have been used in different experimental species, the specific targeting of reperfusion injury by GYY4137 in this study is novel. Several studies have investigated the effect of H 2 S against myocardial ischemia-reperfusion when commercially available sulfide salts were perfused or given pre-ischemia. For example, Johansen et al. (2006) were the first to show that NaSH limited infarct size in a rat isolated heart preparation, while Pan et al. (2009) Chuah et al (2007) reported that allitridum and S-allylcysteine respectively also elicited cardioprotection against myocardial infarction when given before ischemia. Preconditioning the heart with the thiol derivative S-diclofenac was also protective partially through the opening of mitochondrial K ATP channels (Rossoni et al., 2008) . Investigators also have examined the possibility of postconditioning the myocardium using NaSH and Na 2 S.
For example, Elrod et al. (2007) , Sodha et al. (2009) and Lambert et al. (2014) all reported that Na 2 S protected mouse heart against myocardial infarction in vivo when given at reperfusion. Bibli et al. (2015) showed that a bolus dose of NaSH 10 minutes before reperfusion then continuous infusion of NaSH till the end of reperfusion was required to significantly exert cardioprotection in rabbit. In comparison with these results, in this study we showed that a single bolus dose of GYY4137 at reperfusion had a significant cardioprotective effect against myocardial infarction in the rat. To our knowledge, the only other long-lasting H 2 S donors that have been reported are the polysulfide diallyl trisulfide (DATS) and SG-1002, a thiolactivated H 2 S donor. Despite generating 10 times less H 2 S than Na 2 S, DATS was shown to improve mitochondrial respiration and stimulate eNOS at reperfusion in an in vivo mouse model of ischemia-reperfusion injury. However, DATS is a polysulfide compound, and thus cannot be considered a pure H 2 S donor with the possibility of off-target effects. Moreover, H 2 S release from GYY4137 is reported to last longer compare to DATS (Li et al., 2008 , Predmore et al., 2012 . In the setting of pressureoverload-induced heart failure, SG-1002-treated hearts were protected during transverse aortic constriction via triggering VEGF/Akt/eNOS/NO/cGMP pathway.
Recently, SG-1002 has successfully passed Phase I clinical study in patient with heart failure (ClinicalTrials.gov #NCT01989208 and #NCT02278276), by increasing blood H 2 S level and circulating NO bioavailability . However, none of these studies have shown that the observed effects are due to H 2 S release due to the lack of negative control (like depleted GYY4137, for example). Therefore, there is persuasive experimental evidence that a stable level of H 2 S release confers effective cardioprotection against ischemia-reperfusion injury. The present study confirms for the first time that administration of GYY4137 prior to reperfusion (postconditioning), rather than prior to coronary artery occlusion (preconditioning), exerts a marked cardioprotective effect due to H 2 S-releasing capacity.
GYY4137 postconditioning activates PI3K/Akt signalling
The second series of experiments aimed to explore the signalling mechanisms underpinning the protective effect of GYY4137. The involvement during early reperfusion of specific kinase mechanisms, notably activation of PI3K/Akt and/or ERK1/2, activation of eNOS and inhibition of GSK-3, has attracted considerable attention in relation to cardiac conditioning phenomena, especially postconditioning.
Elucidation of the RISK pathway has confirmed that it is a key modulator of protection against reperfusion injury in many species, although not all. Here, we explored the effects of pharmacological inhibition of two key components, PI3K/Akt and eNOS, confirmed by assessment of the phosphorylation status of these proteins.
We found that the PI3K inhibitor LY294002 abrogated the infarct-limiting effect of GYY4137 which indicated the involvement of PI3K/Akt survival pathway in cardioprotection established by GYY4137. This was supported by the observation that GYY4137 increased Akt phosphorylation in left ventricular myocardium during early reperfusion, an effect abolished by LY294002. Li et al. (2015a) showed that NaSH at reperfusion limited cell death by activating PI3K/Akt pathway in aging rat heart and cardiomyocytes. However, Lambert et al. (2014) demonstrated that in diabetic rats NaSH-induced postconditioning might signal through the other arm of the RISK pathway, namely ERK1/2. LY294002 alone had no significant effect on either the infarct size or Akt phosphorylation compared to control which is consistent with the findings of other investigators , Barsukevich et al., 2015 .
This suggests that the PI3K/Akt pathway is almost inactive at basal physiological levels of H 2 S.
We also investigated the involvement of ERK1/2 in cardioprotection established by GYY4137. In contrast to Akt phosphorylation, we observed no significant increase in ERK1/2 phosphorylation at early reperfusion following postconditioning with GYY4137. It has been reported by others that a bolus dose of Na 2 S at reperfusion could activate ERK1/2 and also inhibit GSK-3β (Lambert et al., 2014 , Li et al., 2015b , Bibli et al., 2015 . However, since in our hands GSK-3β phosphorylation (leading to enzyme inhibition) by GYY4137 was abrogated by LY294002, this suggests it is downstream of PI3K/Akt, rather than ERK1/2. It again emphasises the physiological differences between bolus sulfide (with NaSH or Na 2 S) and H 2 S generated in a more physiological manner (with GYY4137).
Dependency of GYY4137-postconditioning on NO
Inhibition of NO synthesis using L-NAME had no effect on the infarct size per se which is consistent with other investigators (Fradorf et al., 2010 , Imani et al., 2011 .
This observation implies that NO does not afford any cardioprotection against myocardial infarction at basal physiological levels. GYY4137 treatment induced an increase in the phosphorylation of eNOS at its activating site, ser 1177 suggesting that NO bioavailability is increased following GYY4137 treatment. L-NAME prior to GYY4137 administration limited the phosphorylation of eNOS and partially attenuated infarct limitation but did not completely abolish the protective effect.
These data suggest that enhancing NO bioavailability synergises the cardioprotection of GYY4137 against reperfusion injury but blocking eNOS phosphorylation only partially limits the cardioprotection of GYY4137, suggesting the involvement of parallel NO-independent pathway(s). There has been considerable interest in cross-regulation of NO and H 2 S but the nature of their interactions is uncertain, at least in part because of the large variation in experimental conditions. SG-1002, H 2 S donor, was protective and increased NO bioavailability in an in vivo model of heart failure (Kondo et al., 2013 ). An increase in NO metabolites following DATS treatment was also observed by Lefer and co-workers (2012) in mouse heart. King et al. (2014) found that H 2 S did not limit infarction in eNOS phospho-mutant (S1179A) or eNOS knockout mice. Considered together, these studies suggest that an increase in one of the gaseous mediators can eventually lead to an increase in the other but the picture is obscured by variations across species, pathological models and tissue types. The NO-dependency of H 2 S has recently been studied by Bibli et al. (2015) in an in vivo model of myocardial infarction using two species, rabbit and mouse. Pharmacologically limiting NO availability with L-NAME did not limit the protection of NaSH in rabbits, while genetic mutation or pharmacological blockade of eNOS totally abolished H 2 S-induced protection in mice. Dependency of NaSH-induced cardioprotection on NO in mice was previously reported by Sojitra et al. (2012) . Together and in line with our data, it seems plausible that NO involvement in the infarct-limiting effect of H 2 S could be tissue and/or species-dependent. Further detailed work needs to be carried out for better understanding of the molecular pharmacology of these molecules and to enhance the clinical implementation of H 2 Sdelivering systems.
GYY4137 postconditioning attenuates GSK-3β phosphorylation
GSK-3β has been proposed as one of the key end effectors of some cardioprotective manoeuvres, particularly ischemic conditioning phenomena. It has been demonstrated that GSK-3β promotes the opening of mPTP during reperfusion, an event thought to be a major determinant of cell death (Cabrera-Fuentes et al., 2016) .
In isolated cardiomyocytes, Yao et al. (2010) and Li et al. (2015b) found that NaSH protected against hypoxia/reoxygenation induced cell death by inhibiting GSK-3β-dependent opening of mPTP. In line with these results, the present study demonstrated that GYY4137 increased the phosphorylation of GSK-3β at Ser 9 site at reperfusion. This was abolished by LY294002, but not by L-NAME, suggesting that GYY4137 induced inhibition of GSK-3β is downstream of PI3K/Akt. There is evidence that the increase in Akt phosphorylation (Hausenloy et al., 2009) and NO bioavailability (Burley et al., 2007) at early reperfusion may also inhibit the opening of mPTP. Considering these data together, it seems plausible that postconditioning with GYY4137 is associated with a reduced susceptibility of mPTP opening, although this remains to be determined by specific measurements of mPTP opening.
Study limitations
There are still questions which this study did not address and they could be interesting topics for further investigations. This study found that GYY4137 activates the RISK pathway at early minutes of reperfusion to limit the infarct size where infarction was quantified after 2 hours of reperfusion. Nevertheless, whether GYY4137 could exert a comparable cardioprotection via similar or different mechanism(s) with longer reperfusion protocol, where there could be no-flow phenomena or late apoptosis, needs to be investigated. Although spent-GYY4137
did not exert any cardioprotection, the direct effect of GYY4137 administration on the level of H 2 S in the heart and circulation needs to be measured. Similarly, measuring the proposed elevation in NO bioavailability as a result of activating eNOS at reperfusion by GYY4137 administration could also underpin the conclusion.
Conclusion
In summary, we have demonstrated that the slow-releasing H 2 S donor GYY4137, but not its H 2 S-depleted control, protected the heart against lethal reperfusion injury when administered as an adjunct treatment prior to reperfusion. This cardioprotective action is dependent on activation of PI3K/Akt signalling pathway at early reperfusion, which in turn, increases NO bioavailability by increasing eNOS phosphorylation, and increases the phosphorylation of GSK-3β (see Figure 5 , Graphical Abstract). Thus, stable slow-releasing H 2 S donor compounds may be promising candidates for the development of adjunct therapies to reperfusion for the treatment of acute myocardial infarction. induced by GYY4137 treatment.
Although not yet determined, it seems plausible that GYY4137 eventually inhibits the opening of mPTP at early reperfusion as a result of the increase in NO level and inhibition GSK-3β activity, resulting in reduced cardiomyocyte susceptibility to lethal reperfusion injury. Table 1 .
Baseline and cardiodynamics for series 1 and 2 at the end of stabilisation period, after 20 minutes of ischaemia and at the end of reperfusion. 
